EUCTR2018-001991-39-DE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF). - DeFi
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participant must be at least 18 years of age at the time of signing the informed consent.
- •2. Participant has histologically confirmed DT/AF that has progressed by >=20% as measured by RECIST v1.1 within 12 months of the screening visit scan.
- •3. Participant has:
- •a. Treatment naïve, measurably progressing DT/AF that is deemed not amenable to surgery without the risk of significant morbidity;
- •b. Recurrent, measurably progressing DT/AF following at least one line of therapy;
- •c. Refractory, measurably progressing DT/AF following at least one line of therapy.
- •4. Participant has a DT/AF tumor where continued progressive disease will not result in immediate significant risk to the participant.
- •5. Participant agrees to provide archival or new tumor tissue for reconfirmation of disease.
- •6. If participant is currently being treated with any therapy for the treatment of DT/AF, this must be completed at least 28 days (or 5 halflives,
- •whichever is longer) prior to first dose of study treatment. All toxicities from prior therapy must be resolved to =< Grade 1 or clinical baseline.
- •7. Participants who are receiving chronic nonsteroidal anti-inflammatory drugs (NSAIDs) as treatment for conditions other than DT/AF must be
- •receiving them prior to the documented DT/AF progressive disease (inclusion criteria 2) and on a stable dose for at least 28 days prior to first dose of study treatment.
- •8. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status =< 2 at screening (refer to Section 10.7 for ECOG performance status scale).
- •9. Participant has adequate organ and bone marrow function as defined by the following screening laboratory values:
- •a. Absolute neutrophil count >= 1500 cells/µL;
- •b. Platelets >= 100,000µL;
- •c. Hemoglobin >= 9 g/dL;
- •d. Total bilirubin =< 1.5 x upper limit of normal (ULN) (isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%);
- •e. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase) =< 2 x ULN; and
- •f. Serum creatinine =< 1.5 x ULN or if creatinine > 1.5 x ULN then calculated creatinine clearance must be >= 60 mL/min (using the Cockcroft-Gault formula);
- •10. Participant can swallow tablets and has no gastrointestinal conditions affecting absorption.
- •11. Male or Female
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •a. Male participants:
- •Male participants are eligible to participate if they agree to the following during the treatment period and for at least 90 days after the last dose
- •of study treatment:
- •Refrain from donating or preserving sperm;
- •PLUS either:
- •Be abstinent from sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent;
- •Must agree to use a male condom when having sexual intercourse with women of childbearing potential (WOCBP). An additional form of
- •contraception should also be used by the female partner, if she is of childbearing potential.
- •b. Female participants:
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not of childbearing potential (not WOCBP).
- •Is of childbearing potential but is abstinent or using 1 highly effective contraceptive method, duri
排除标准
- •1. Participant has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat (e.g., gastric bypass, lap band, or other gastric procedures that would alter absorption); delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed.
- •2. Participant has experienced any of the following within 6 months of signing informed consent:
- •clinically significant cardiac disease (New York Heart Association Class III or IV);
- •myocardial infarction;
- •severe/unstable angina;
- •coronary/peripheral artery bypass graft;
- •symptomatic congestive heart failure;
- •cerebrovascular accident;
- •transient ischemic attack; or
- •symptomatic pulmonary embolism.
- •3. Participant has abnormal QT interval corrected by Fridericia's formula (> 450 msec for male participants, > 470 msec for female participants,
- •or > 480 msec for participants with bundle branch block) after electrolytes have been corrected (triplicate ECG readings, done approximately 2-3 minutes apart and averaged) at screening.
- •4. Participant is using concomitant medications that are known to prolong the QT/QTcF interval including Class Ia (e.g., quinidine, procainamide, disopromide) and Class III (e.g., dofetilide, ibutilide, sotalol) antiarrhythmics at the time of informed consent. Nonantiarrhythmic medications which may prolong the QT/QTcF interval are allowed provided the participant does not have additional risk factors for Torsades de Pointes (TdP).
- •5. Participant has congenital long QT syndrome.
- •6. Participant has a history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
- •7. Participant has had lymphoma, leukemia, or any malignancy within the past 5 years at the time of informed consent, except for any locally
- •recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ
- •of the cervix or breast), with no evidence of metastatic disease for 3 years at the time of informed consent.
- •8. Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
- •9. Participant previously received or is currently receiving therapy with GS inhibitors or anti-Notch antibody therapy.
- •10. Participant is currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs), NSAIDs (chronic daily use – except as in inclusion criterion 7) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment.
- •Participant has started any treatment for DT/AF after the documented DT/AF progressive disease (inclusion criteria 2).
- •11. Participant is currently using or anticipates using food or drugs that are known strong/moderate cytochrome P450 3A4 (CYP3A4) inhibitors,
- •or strong CYP3A inducers within 14 days prior to the first dose of study treatment.
- •12. Participant is currently enrolled or was enrolled within 28 days of first dose of study treatment in another clinical study with any investigational drug or device. Participation in observational studies may be permitted with prior approval from the medical monitor/sponsor.
- •13. Participant has a positive human immunodeficiency virus antibody test.
- •14. Participant has presence of Hepatitis B surface antigen at screening.
- •15. Participant has a positive Hepatitis C antibody o
研究者
相似试验
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-SEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Soft Tissue SarcomaAdvanced or Metastatic Soft Tissue SarcomaMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2015-000134-30-PLEli Lilly and Company460
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-BEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-DEEli Lilly & Company280
进行中（未招募）
1 期
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.Hereditary Angioedema Type I or IIMedDRA version: 21.0Level: LLTClassification code 10080956Term: Hereditary angioedema type ISystem Organ Class: 100000004850MedDRA version: 24.0Level: LLTClassification code 10080960Term: Hereditary angioedema type IISystem Organ Class: 100000004850EUCTR2021-000136-59-BGKalvista Pharmaceuticals Ltd48